COHANCE
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; … Read more
COHANCE (COHANCE) - Net Assets
Latest net assets as of September 2025: ₹39.25 Billion INR
Based on the latest financial reports, COHANCE (COHANCE) has net assets worth ₹39.25 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹55.68 Billion) and total liabilities (₹16.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹39.25 Billion |
| % of Total Assets | 70.48% |
| Annual Growth Rate | 20.86% |
| 5-Year Change | 55.88% |
| 10-Year Change | N/A |
| Growth Volatility | 17.98 |
COHANCE - Net Assets Trend (2019–2025)
This chart illustrates how COHANCE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for COHANCE (2019–2025)
The table below shows the annual net assets of COHANCE from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹18.41 Billion | -10.24% |
| 2024-03-31 | ₹20.51 Billion | +18.18% |
| 2023-03-31 | ₹17.35 Billion | +13.62% |
| 2022-03-31 | ₹15.27 Billion | +29.33% |
| 2021-03-31 | ₹11.81 Billion | +39.78% |
| 2020-03-31 | ₹8.45 Billion | +43.11% |
| 2019-03-31 | ₹5.90 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to COHANCE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 285.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹15.08 Billion | 88.90% |
| Common Stock | ₹254.60 Million | 1.50% |
| Other Comprehensive Income | ₹532.80 Million | 3.14% |
| Other Components | ₹1.10 Billion | 6.46% |
| Total Equity | ₹16.97 Billion | 100.00% |
COHANCE Competitors by Market Cap
The table below lists competitors of COHANCE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tianjin Port Development Holdings Limited
PINK:TJIPY
|
$531.23 Million |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
$531.25 Million |
|
Stabilus S.A
PINK:SIUAF
|
$531.30 Million |
|
Trican Well Service Ltd.
PINK:TOLWF
|
$531.32 Million |
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
$530.99 Million |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
$530.73 Million |
|
Delta Galil Industries Ltd
OTCGREY:DELTF
|
$530.69 Million |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
$530.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COHANCE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,506,635,000 to 16,965,800,000, a change of -3,540,835,000 (-17.3%).
- Net income of 2,678,700,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 972,352,001.
- Other factors decreased equity by 5,247,182,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹2.68 Billion | +15.79% |
| Other Comprehensive Income | ₹-972.35 Million | -5.73% |
| Other Changes | ₹-5.25 Billion | -30.93% |
| Total Change | ₹- | -17.27% |
Book Value vs Market Value Analysis
This analysis compares COHANCE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 12.99x to 4.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | ₹23.19 | ₹301.25 | x |
| 2020-03-31 | ₹33.18 | ₹301.25 | x |
| 2021-03-31 | ₹46.39 | ₹301.25 | x |
| 2022-03-31 | ₹59.99 | ₹301.25 | x |
| 2023-03-31 | ₹68.16 | ₹301.25 | x |
| 2024-03-31 | ₹80.56 | ₹301.25 | x |
| 2025-03-31 | ₹66.32 | ₹301.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COHANCE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.79%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.37%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.79x
- Recent ROE (15.79%) is below the historical average (28.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 44.43% | 28.92% | 1.16x | 1.33x | ₹2.03 Billion |
| 2020 | 37.53% | 38.02% | 0.71x | 1.39x | ₹2.33 Billion |
| 2021 | 30.69% | 35.89% | 0.68x | 1.25x | ₹2.44 Billion |
| 2022 | 29.72% | 34.37% | 0.72x | 1.20x | ₹3.01 Billion |
| 2023 | 23.70% | 30.69% | 0.68x | 1.13x | ₹2.38 Billion |
| 2024 | 14.64% | 28.56% | 0.47x | 1.10x | ₹952.14 Million |
| 2025 | 15.79% | 22.37% | 0.40x | 1.79x | ₹982.12 Million |
Industry Comparison
This section compares COHANCE's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COHANCE (COHANCE) | ₹39.25 Billion | 44.43% | 0.42x | $531.19 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |